TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02919059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 4 mg
Description: Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal.
Study: NCT02909244

Intervention type: BIOLOGICAL
Intervention: Biological sampling
Description: Biological sampling
Study: NCT03183856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning walk
Description: a end-effector typed gait robot with a saddle
Study: NCT02452034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV solution
Description: Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
Study: NCT03183856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no Morning walk
Description: ambulation voluntary or with a help of walker
Study: NCT02944981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Single oral dose
Study: NCT02452034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV solution
Description: Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV solution
Description: Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
Study: NCT02944981

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study: NCT00296309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Immunosuppression
Study: NCT02452034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole powder for oral suspension
Description: Posaconazole once daily by PFS for a minimum of 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole powder for oral suspension
Description: Posaconazole once daily by PFS for a minimum of 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole powder for oral suspension
Description: Posaconazole once daily by PFS for a minimum of 10 days
Study: NCT00296309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppression
Study: NCT00321672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGX-4010, 8% capsaicin patch
Description: Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: 0.04% capsaicin patch
Description: Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGX-4010, 8% capsaicin patch
Description: Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: 0.04% capsaicin patch
Description: Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
Study: NCT01670526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivastigmine Transdermal Patch
Description: Cholinesterase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine Transdermal Patch
Description: Cholinesterase Inhibitor
Study: NCT01667159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy
Description: Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
Study: NCT02831426

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage with Acellular Dermal Matrix (CELLIS® Breast)
Description: After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by an ADM (CELLIS® Breast, MECCELLIS BIOTECH, 40 rue Chef de Baie, 17000, La Rochelle FRANCE) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
Study: NCT01511211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
Study: NCT00450034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drug - oriented multifaceted intervention
Description: oriented multifaceted intervention
Study: NCT00901810

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Apex Locator
Description: Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Radiography
Description: Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
Study: NCT03327740

Intervention type: DRUG
Intervention: DTG based ARV regimen with ABC
Description: ARV regimens containing DTG and ABC

Intervention type: DRUG
Intervention: DTG based ARV regimen without ABC
Description: DTG based ARV regimens that do not contain ABC

Intervention type: DRUG
Intervention: RAL or EGV based ARV regimens with ABC
Description: RAL or EGV based regimens containing ABC

Intervention type: DRUG
Intervention: RAL or EGV based regimens without ABC
Description: RAL or EGV based ARV regimens that do not contain ABC

Intervention type: DRUG
Intervention: Any other DTG based ARV regimen as monotherapy
Description: Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
Study: NCT03467035

Intervention type: OTHER
Intervention: Inflammasone
Description: Serum level of cytokine and RT-PCR for PBMC
Study: NCT02831426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)
Description: After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by a Titanium Coated Polypropylene Mesh (TiLOOOP® Bra, pfm medical, ag Wankelstraße 60 ,50996 Köln GERMANY) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
Study: NCT03842644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tension reduction device
Description: Continue using this device for 3 months post surgery.
Study: NCT04122170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (ASA) Oral Tablet - Pre-Treatment
Description: Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin (ASA) Oral Tablet - Pre-Treatment
Description: Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bentracimab (PB2452) Infusion
Description: Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% Sodium chloride) infusion
Description: 0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
Study: NCT01196962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central venous catheter
Description: Central venous catheter insertion to subclavian vein
Study: NCT00908037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: thrombopoietin receptor agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for comparison
Study: NCT02661672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Device
Description: The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artemis Device
Description: The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
Study: NCT00642863

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate (liquid) + vitamins A and D
Description: a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate (liquid) + vitamins A and D
Description: a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamins A and D
Description: a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamins A and D
Description: a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (liquid)
Description: Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (liquid)
Description: Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (liquid)
Description: Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
Study: NCT01364701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 100 mg
Description: 4 tablets for on demand use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 20 mg
Description: 4 tablets on demand

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination half of maximal dose for sildenafil & tadalafil
Description: 4 tablets on demand
Study: NCT03046524

Intervention type: OTHER
Intervention: Chart Review
Description: Data between the years of 1/1/2002 and 12/31/2013 analyzed.

Intervention type: OTHER
Intervention: Chart Review
Description: Data between the years of 1/1/2002 and 12/31/2013 analyzed.
Study: NCT05094830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stomach Intestinal Pylorus-Sparing (SIPS) Procedure
Description: The SIPS procedure will be performed as an investigational bariatric surgery. The SIPS procedure involves the creation of a standard sleeve gastrectomy over a 36-40 bougie. Division of the duodenum post-pylorus is performed, followed by the creation of a common channel 300 cm from the ileo-cecal valve. A hand-sewn anti-side duodenoileostomy is performed and the anastomosis tested for leaks through use of endoscopic insufflation and under water air leak test. Incisions are then closed in standard fashion. The SIPS procedure itself is not a separate surgery but rather a modification to the standard of care surgery.
Study: NCT03530670

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral midazolam
Description: 0.5 mg/kg oral midazolam administered 20 minutes before anesthesia induction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.
Description: Patients will be watched a short movie (at URL:~http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) 20 minutes before induction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Playing smartphone game
Description: Patients will be played with smartphone (angry birds, subway surfers or snail Bob) 20 minutes before induction
Study: NCT02153060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
Study: NCT03336385

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Naxus
Description: Non-digestible polysaccharides arabinoxylan (Naxus)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oatwell
Description: Non-digestible polysaccharides oat beta-glucan (Oatwell)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin as placebo
Study: NCT01033318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809
Study: NCT00389922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: comparative genomic hybridization
Description: Molecular correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Molecular correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Molecular correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Molecular correlative study
Study: NCT01033318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1809
Description: single oral doses of MK1809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan
Study: NCT00389922

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Molecular correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Molecular correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Description: Molecular correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Molecular correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Molecular correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Molecular correlative study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine ditartrate
Description: Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
Study: NCT01033318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan
Study: NCT01811693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerly Trinitrate
Description: 5mg/24hour (0.2mg/hour) transdermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerly Trinitrate
Description: 10mg/24hour (0.4mg/hour) transdermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerly Trinitrate
Description: 10mg/24hour (0.4mg/hour) transdermal
Study: NCT01033318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan
Study: NCT01811693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerly Trinitrate
Description: 0.4 mg sublingual single metered spray
Study: NCT01244503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Octanoate Breath Test
Description: 100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
Study: NCT00762112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559
Description: TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
Study: NCT01082497

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness training
Description: A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
Study: NCT01033318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Losartan
Description: single oral doses of 100 mg Losartan